Demoly P, Corren J, Creticos P, et al. - This phase III, international, double-blind, placebo-controlled, randomized clinical trial was undertaken to test efficacy as well as safety of a 300 index of reactivity (IR) sublingual tablet formulation of Dermatophagoides pteronyssinus: Dermatophagoides farinae 1:1 extract among adolescents (aged ≥12) and adults suffering from moderate-to-severe house dust mite (HDM)-induced allergic rhinitis (AR). The patients were administered nearly 12 months of treatment with placebo or the 300°IR tablet. The average total combined score (aTCS) during 4 weeks at the end of the treatment span was the primary endpoint. Significantly lower least squares mean aTCS was found in the 300°IR group (3.62) vs placebo group (4.35), over the primary assessment duration, with a relative least squares mean difference of -16.9%. The general good tolerability of 300°IR tablet was reported. Overall, findings demonstrated the safety as well as the effectiveness of the 300°IR sublingual HDM tablet in the treatment of HDM-induced AR.